Clinical Trials Logo

Diabetes Mellitus, Type 2 clinical trials

View clinical trials related to Diabetes Mellitus, Type 2.

Filter by:

NCT ID: NCT03821753 Completed - Diabetes Clinical Trials

The Effect of the Glycemic Variability on Macular Retinal Microcirculation and Cognitive Functions in Patient With Type 1 Diabetes

REVADIAB
Start date: January 7, 2019
Phase:
Study type: Observational

Revadiab is case-control study aimed to demonstrate that retinal capillary density is altered in patients with type 1 diabetes with glycemic variability compared to those with comparable glycemic control without glycemic variability. An OCT angiography will be used to precisely evaluate retinal capillary density. A secondary objective will be to evaluate if glycemic variability is associated with cognitive dysfunction, using a neuro psychologic evaluation.

NCT ID: NCT03821675 Completed - Diabetes Clinical Trials

Electrical Stimulation to Accelerate Wound Healing

Start date: February 28, 2019
Phase: N/A
Study type: Interventional

A clinical study at the Baylor College of Medicine, Division of Vascular Surgery and Endovascular Therapy, is being proposed to test the efficacy of a novel electrical stimulation platform named the Tennant Biomodulator designed by AVAZZIA to accelerate wound healing, relieve pain and improve mobility in patients with diabetic foot ulcers.

NCT ID: NCT03821662 Completed - Clinical trials for Diabetes Mellitus, Type 2

OT-Led Interdisciplinary Diabetes Self-Management Prgm

Start date: April 11, 2019
Phase: N/A
Study type: Interventional

This study proposes to introduce an outpatient Occupational Therapy (OT)-led diabetes intervention program. OTs with training in diabetes self-management modules that address physical, social, emotional, and systemic factors that influence health. Patients receiving outpatient OT services for development of diabetes self-management skills will be seen for approximately 8 forty five-minute to one-hour sessions over 6 months. OTs will communicate with other interdisciplinary care team members using Electronic Health Record (EHR) messaging, phone calls, and in-person communication as needed. There will be at minimum a monthly consult meeting with a doctor of psychology (Psy D), registered dietitian (RD), social worker (SW), and pharmacist (PharmD), and the primary care medical team will be provided with monthly progress notes. The investigators hypothesize that participants demonstrate improved blood sugar levels, improved ability to take medications as directed, increases in overall sense of physical, mental, and social health, and positive changes in their self-efficacy related to diabetes self-management. The investigators also hypothesize that OT visits will be reimbursed by insurers more than 50% of all billed visits.

NCT ID: NCT03820752 Completed - Diabetes Clinical Trials

Vaccination Coverage and Level of Protection in Patients at Risk

Start date: October 2014
Phase:
Study type: Observational

The purpose of this study is to determine 1. vaccination coverage of recommended vaccines (routine childhood vaccines and vaccines against seasonal flu and pneumococci) in children with chronic diseases (allergy, cystic fibrosis, diabetes mellitus type 1, congenital heart disease, immunocompromised and solid organ transplant patients) 2. the level of protection against measles, mumps, rubella and pertussis in children with chronic diseases. 3. vaccination coverage of recommended vaccines (diphtheria, tetanus, pertussis and vaccines against seasonal flu and pneumococci) in adults with chronic diseases (nephropathy, diabetes mellitus, COPD, heart failure, HIV and solid organ transplant patients) 4. the level of protection against diphtheria, tetanus and pertussis in adults with chronic diseases.

NCT ID: NCT03820050 Completed - Diabetes Mellitus Clinical Trials

FreeStyle LIbre Flash Glucose Monitoring System Pediatric Accuracy Study

Start date: January 29, 2019
Phase:
Study type: Observational

The purpose of this study is to characterize the Freestyle Libre Flash Glucose Monitoring System in pediatric subjects with respect to YSI reference venous plasma sample measurements.

NCT ID: NCT03819790 Completed - Clinical trials for Diabetes Mellitus, Type 2

The Effect of Soliqua on Glucose Variability in Type 2 Patients Among South Asians

VARIATION 2 SA
Start date: October 2, 2018
Phase: Phase 4
Study type: Interventional

The overall objective of this study is to compare the effects of Soliqua, a titratable combination of insulin and GLP-1 receptor agonist in a single pen versus Glargine U100 insulin (Basaglar or Lantus) and gliclazide MR, both added to metformin, on measures of glucose variability using masked CGM data among people of South Asian origin living in Canada with type 2 diabetes (T2DM).

NCT ID: NCT03819335 Completed - Clinical trials for Diabetes Mellitus, Type 1

¿Can mySugr App Improve Knowledge and Self-management of People With Type 1 Diabetes Mellitus?

Start date: April 9, 2019
Phase: N/A
Study type: Interventional

This project is based on the contribution that an app can offer for improving knowledge and self-management of people with type 1 diabetes. The main objective of this study is to assess mySugr app as a tool for empowering people with type 1 diabetes. The study population are type 1 diabetes people, aged more than 18 years old and with more than one year from diagnosis. They will be randomised to standard care or use of mySugr app and will be followed-up during 48 weeks. Control group will attend 5 face-to-face visits (baseline, 3, 6, 9 and 12 months) with the possibility of telephone contact and hospital assistance if necessary. Intervention group will attend 3 face-to-face visits (baseline, 6 and 12 months) and 2 telematic visits (at 3 and 9 months) and will also have the possibility of telephone contact and hospital assistance if necessary.

NCT ID: NCT03817749 Completed - Clinical trials for Overweight and Obesity

Ketone Supplementation, Glucose Control, and Cardiovascular Function

Start date: February 6, 2019
Phase: N/A
Study type: Interventional

Post-prandial hyperglycemic excursions induce a cascade of deleterious effects on the body, including increased inflammation, production of reactive oxygen species, and impaired cardiovascular function. Ingestion of an exogenous oral ketone supplement blunts hyperglycemia in response to an oral glucose tolerance test. Accordingly, it is hypothesized that exogenous ketone supplement ingestion prior to a meal could be an effective strategy for blunting postprandial hyperglycemia. Therefore, the purpose of this study is to investigate the effect of short-term (14-days) pre-meal exogenous ketone supplementation on glucose control, cardiovascular function, inflammation, and oxidative stress in individuals at an elevated risk of type 2 diabetes.

NCT ID: NCT03817463 Completed - Clinical trials for Diabetes Mellitus, Type 2

A Study to Observe the Effectiveness of Empagliflozin, Other SGLT-2 Inhibitors, or DPP-4 Inhibitors in Patients With Type 2 Diabetes

Start date: April 15, 2019
Phase:
Study type: Observational

Non-interventional, multi-country cohort study using existing data and including adults (≥18 years) with a diagnosis of Type 2 diabetes mellitus.

NCT ID: NCT03816761 Completed - Clinical trials for Diabetes Mellitus, Type 1

Research Study to Look at Fast-acting Insulin Aspart With the Insulin Pump System 'iLet™' in Adults With Type 1 Diabetes

Start date: February 25, 2019
Phase: Phase 2
Study type: Interventional

The iLet™ is a new insulin pump that is programmed to work with a Continuous Glucose Monitoring (CGM) device. This is to give participants insulin automatically. The CGM device is already available for sale. The iLet™ is not yet approved for use. Fast-acting insulin aspart is a type of insulin that doctors can already prescribe for use with insulin pens, but not for use in an insulin pump. This study is to test how safe fast acting insulin aspart is when used with different insulin delivery settings in the iLet™ in people with type 1 diabetes. Participants will get fast-acting insulin aspart as participants' insulin and use the iLet™ as participants' insulin pump with a CGM device. Participants' iLet™ will be set to 2 different insulin delivery settings for 7 days on each setting. The setting participants get first is decided by chance. The study will last for about 5 to 9 weeks. Participants will have 4 visits and 1 phone contact with the study or staff.